Malignant melanoma is the most lethal type of skin cancer with high rates of mortality.
Although current treatment options provide a short-clinical benefit, acquired-drug resistance …

It has been for long conceived that hallmarks of cancer were intrinsic genetic features driving
tumor development, proliferation, and progression, and that targeting such cell-autonomous …

Background Long intergenic non-protein coding RNA 520 (LINC00520), a novel identified
lncRNA, has been shown to modulate the malignant phenotype of tumor cells in some …

Simple Summary Improvement in melanoma patients with metastatic disease is needed to
better assess immunotherapies. Lactate dehydrogenase (LDH) is currently an accepted …

Melanoma is the leading cause of skin cancer deaths in the United States, and its incidence
has been rising steadily for the past 30 years (Aftab, Dinger, & Perera, 2014). A more …

The identification of key driver mutations in melanoma has led to the development of
targeted therapies aimed at BRAF and MEK, but responses are often limited in duration …

Advances in the use of targeted and immune therapies have revolutionized the clinical
management of melanoma patients, prolonging significantly their overall and progression …

CRISPR-based screening methods using single-cell RNA sequencing (scRNA-seq)
technology enable comprehensive profiling of gene perturbations from knock-out mutations …

Immune checkpoint blockade therapy has changed prognoses for many melanoma patients.
However, immune responses that correlate with clinical progression of the disease are still …

Acquired tumor resistance to cancer therapies poses major challenges in the treatment of
cancers including melanoma. Among several signaling pathways or factors that affect …